Investigational Drug Information for threo-3-methyl-L-aspartic acid
✉ Email this page to a colleague
What is the development status for investigational drug threo-3-methyl-L-aspartic acid?
threo-3-methyl-L-aspartic acid is an investigational drug.
There have been 7 clinical trials for threo-3-methyl-L-aspartic acid.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2008.
The most common disease conditions in clinical trials are Hypotension, Orthostatic, Hypotension, and Autonomic Nervous System Diseases. The leading clinical trial sponsors are Chelsea Therapeutics, Chiltern International Inc., and University Hospital, Toulouse.
Summary for threo-3-methyl-L-aspartic acid
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 5 |
WIPO Patent Applications | 2 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 3 (2008-01-01) |
Vendors | 17 |
Recent Clinical Trials for threo-3-methyl-L-aspartic acid
Title | Sponsor | Phase |
---|---|---|
Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA | University Hospital, Toulouse | Phase 2/Phase 3 |
Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome | Chelsea Therapeutics | Phase 2 |
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease | Chelsea Therapeutics | Phase 3 |
Clinical Trial Summary for threo-3-methyl-L-aspartic acid
Top disease conditions for threo-3-methyl-L-aspartic acid
Top clinical trial sponsors for threo-3-methyl-L-aspartic acid
US Patents for threo-3-methyl-L-aspartic acid
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |